Aroa Biosurgery Ltd (AU:ARX)
ASX:ARX
Want to see AU:ARX full AI Analyst Report?
ARX Stock Chart & Stats
AU$0.53
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.53
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.46 - AU$0.80
Previous CloseN/A
Volume195.72K
Average Volume (3M)302.12K
Market Cap
AU$233.48M
Enterprise ValueAU$227.87M
Total Cash (Recent Filing)AU$22.60M
Total Debt (Recent Filing)AU$5.31M
Price to Earnings (P/E)66.8
Beta0.56
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding345,902,650
10 Day Avg. Volume330,836
30 Day Avg. Volume302,123
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)2.48
Price to Sales (P/S)2.23
P/FCF Ratio24.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.08Price Target Upside103.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth & Profitability InflectionMulti-year top-line expansion alongside a recent shift to positive EBIT and net income demonstrates the business has moved from scale-focused losses toward operating profitability. This structural revenue base and profitability inflection support longer-term investment in sales, clinical adoption, and margin expansion over 2–6 months and beyond.
Conservative Balance Sheet With Low LeverageVery low leverage and substantial equity give the company durable financial flexibility to fund working capital, product development, and commercial expansion without immediate refinancing pressure. A conservatively levered balance sheet reduces bankruptcy and liquidity risk and supports consistent execution over the medium term.
Turnaround To Positive Operating & Free Cash FlowConversion of earnings into positive operating and free cash flow materially strengthens internal funding capacity for capex, R&D and working capital. A near-1x FCF-to-profit ratio is a durable quality-of-earnings signal that, if sustained, reduces dependence on external capital and supports strategic investments.
Bears Say
Profitability Consistency RiskAlthough 2026 shows positive net income, multi-year prior losses and a still-modest net margin imply profits are not yet proven through a full cycle. Smaller margins leave earnings exposed to reimbursement shifts, input-cost increases, or slower surgical volumes, raising the risk of margin compression over the medium term.
Historical Cash-flow VolatilityThe sharp swing to positive cash flow is encouraging but follows multiple years of material negative cash generation. That historical volatility signals execution and conversion risk; sustained positive cash generation is required to ensure reliable funding for growth and to avoid episodic external financing needs.
Dependence On Distributors And OEM/private-label PartnersHeavy reliance on third-party distributors and OEM/private-label relationships limits direct control over commercialization, pricing and clinical roll-out. Partner execution and contract terms materially influence sales growth and margins, creating structural concentration and execution risk that can persist over several quarters.
Aroa Biosurgery Ltd News
ARX FAQ
What was Aroa Biosurgery Ltd’s price range in the past 12 months?
Aroa Biosurgery Ltd lowest share price was AU$0.46 and its highest was AU$0.80 in the past 12 months.
What is Aroa Biosurgery Ltd’s market cap?
Aroa Biosurgery Ltd’s market cap is AU$233.48M.
When is Aroa Biosurgery Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aroa Biosurgery Ltd’s earnings last quarter?
Currently, no data Available
Is Aroa Biosurgery Ltd overvalued?
According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Undervalued.
Does Aroa Biosurgery Ltd pay dividends?
Aroa Biosurgery Ltd does not currently pay dividends.
What is Aroa Biosurgery Ltd’s EPS estimate?
Aroa Biosurgery Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aroa Biosurgery Ltd have?
Aroa Biosurgery Ltd has 345,902,650 shares outstanding.
What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?
Currently, no hedge funds are holding shares in AU:ARX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aroa Biosurgery Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$1.08 (103.14% Upside)
AU$1.08 (103.14% Upside)
Blogger Sentiment
Bullish
AU:ARX Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
4.20%
Trailing 12-Months
Asset Growth
1.55%
Trailing 12-Months
Company Description
Aroa Biosurgery Ltd
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
ARX Stock 12 Month Forecast
Average Price Target
AU$1.08
▲(103.14% Upside)
Technical Analysis
Polynovo
―
Cochlear
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---